You might also be interested in:

German Gin Brand 'GINSTR' Expands to Asia

HONG KONG (ots) - - Cross-reference: Picture is available http://www.presseportal.de/bilder - Over the ...

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an FGFR fusion (PHOTO)

Lausanne, Switzerland (ots) - Patients will be recruited in North America, Europe, South America and the Asia ...

ForaCare Suisse AG forms service-oriented partnership with B. Braun (PHOTO)

St. Gallen (ots) - - Partnership to introduce innovative health management technologies. - Initial product offering ...

29.01.2019 – 19:58

Marinomed Biotech AG

EANS-Adhoc: Marinomed Biotech AG sets offer price at 75 Euro per share

--------------------------------------------------------------------------------
  Disclosed inside information pursuant to article 17 Market Abuse Regulation
  (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
  The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Stock Offerings (IPO)
29.01.2019

Vienna - 29 January 2019. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE
OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA,
AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE
PROHIBITED BY APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE
END OF THIS ANNOUNCEMENT.


* 299,000 new shares (equals to around EUR 22.4 million) placed with investors
  (incl. 39,000 new shares from the over-allotment/Greenshoe)
* Gross proceeds amounts to EUR 19.5 million (excl. over-allotments/Greenshoe)


Marinomed Biotech AG ("Marinomed" or the "company") has set the Offer Price for
new shares of the company in connection with its IPO at 75 Euro per share.

In total, 299,000 new bearer shares were placed with investors. These consist of
260,000 shares from the base offer and 39,000 shares due to over-allotments.

Assuming full exercise of the greenshoe option, gross proceeds will amount to
EUR 22.4 million. The proceeds from the IPO shall be used primarily to fund the
Pivotal Phase III study of Budesolv, Phase II and Phase III studies of Tacrosolv
as well as the extension of the Carragelose® OTC platform.

Based on the total number of 1,299,000 shares (assuming a full exercise of the
greenshoe option) and the Offer Price of EUR 75 per share, the market
capitalization of Marinomed amounts to approximately EUR 97.4 million. The free
float is around 31% (thereof around 22% by from new investors in the IPO). In
case all convertible bonds are converted to new shares of Marinomed Biotech AG,
the free float increases to 39%.

The expected settlement date and first trading day is 1 February 2019. From this
date the Marinomed shares are intended to be traded under the symbol "MARI" on
the official market (prime market segment) of the Vienna Stock Exchange.

The Marinomed Management Board has committed itself to a lock-up period of 36
months, almost all of the other existing shareholders and the company itself to
a lock-up period of 12 months.

The transaction meets the requirements of a qualified public offer in accordance
with the terms and conditions of the convertible bonds issued in 2017 that are
traded on the Third Market of the Vienna Stock Exchange. Convertible bondholders
are thus entitled to convert their bonds into new shares of Marinomed Biotech AG
in accordance with the terms and conditions of the convertible bond. The
conversion period starts with the settlement day (expected to be 1 February
2019) and will run until 14 February 2019, 16:00 CET. The conversion price is
40.8676 Euro.

In this transaction, Marinomed was supported by Erste Group Bank AG as Sole
Global Coordinator and goetzpartners securities Limited as Co-Lead Manager.


About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
development of innovative products derived from patent protected technology
platforms to treat respiratory and ophthalmic conditions. The Carragelose®
platform comprises innovative patent protected products targeting viral
infections of the respiratory tract. Carragelose® is used in nasal sprays,
throat sprays and lozenges, which are sold in more than 30 countries around the
world in collaboration with international partners.The Marinosolv® technology
platform increases the efficacy of hardly soluble compounds for the treatment of
sensitive tissues such as the eyes and nose. Further information is available at
www.marinomed.com [http://www.marinomed.com/].

Disclaimer

This announcement does not constitute an offer to purchase securities or
solicitation of an offer to purchase securities in the United States of America,
Germany, Austria or other jurisdictions. The shares (the "Shares") of Marinomed
Biotech AG (the "Company") may only be sold or offered for sale after prior
registration in the United States of America upon or without prior registration
by virtue of an exemption from the registration requirement under the provisions
of the US Securities Act of 1933, as amended. The Company does not intend to
fully or partially register any offer of Shares in the United States or to make
any public offering of Shares in the United States.

A public offering of securities of the Company in Austria is made solely by, and
on the basis of, a prospectus (including the supplements thereto) for securities
prepared and published in accordance with the provisions of the Capital Markets
Act (Kapitalmarktgesetz), which was approved and published on 16 November 2018.
An investment decision regarding publicly offered securities of the Company
should only be made on the basis of such a prospectus. The prospectus as well as
the supplements thereto are available free of charge at Marinomed Biotech AG,
Veterinärplatz 1, A-1210 Vienna, or on the website of Marinomed Biotech AG
(https://www.marinomed.com/offering).




Further inquiry note:
Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at

end of announcement                         euro adhoc
--------------------------------------------------------------------------------



issuer:       Marinomed Biotech AG
              Veterinärplatz 1
              A-1210 Wien
phone:        0043250774460
FAX:          0043250774493
mail:      office@marinomed.com
WWW:       www.marinomed.com
ISIN:         AT0000A1WD52, ATMARINOMED6
indexes:      
stockmarkets: Wien
language:     English
 

Original content of: Marinomed Biotech AG, transmitted by news aktuell

All Releases
Subscribe to Marinomed Biotech AG
  • Printable version
  • PDF version

Places in this release

Topics in this relase